Digital Therapeutics Market

Digital Therapeutics Market (Application: Treatment/Care and Preventive; and End-user: B2C and B2B) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Digital Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 4.5 Bn in 2022
  • It is projected to advance at a CAGR of 28.6% from 2023 to 2031 and reach US$ 43.2 Bn by the end of 2031

Analysts’ Viewpoint

Rise in usage of smartphones and increase in prevalence of chronic diseases are expected to propel the digital therapeutics market size during the forecast period. Growth in healthcare expenditures and surge in investment in R&D are likely to offer lucrative opportunities to vendors in the global digital therapeutics industry.

Emergence of the COVID-19 pandemic has led to the rapid deployment of remote patient monitoring systems and telemedicine. Growth in accessibility of wearable technology and user-friendly mobile applications and presence of favorable reimbursement policies are estimated to contribute to the digital therapeutics market growth in the near future. Concerns regarding data privacy, legality, and robust clinical proofs are anticipated to limit demand for digital therapeutics during the forecast period.

Digital Therapeutics Market

Market Introduction

The digital therapeutics market, a part of the rapidly growing healthcare industry, focuses on the use of software-based interventions to prevent, manage, or treat various medical conditions. These interventions are intended to supplement conventional medical treatments and are usually provided through internet platforms, wearable technologies, and mobile applications.

The affordability of digital health technology for both patients and providers and increase in adoption of smartphones in developed and developing economies are propelling the digital therapeutics market expansion. According to Kepios, a strategy consultancy, there were 5 billion internet users around the world in April 2022, which accounted for 63% of the global population.

Chronic illnesses, such as diabetes, heart disease, and respiratory conditions, are becoming increasingly common. Improved patient outcomes can be achieved by using digital therapeutics as a convenient and efficient means of managing certain illnesses. Surge in need for affordable solutions and rise in healthcare expenditure are boosting the digital therapeutics market development. Digital therapeutics provide self-management tools, individualized treatment regimens, and remote monitoring to lower healthcare costs.

Rise in Usage of Smartphones Driving Digital Therapeutics Market Value

The way people interact with and access digital technologies, including healthcare solutions, has changed significantly as a result of the widespread adoption of smartphones. For a considerable segment of the world's population, smartphones have become an essential component of everyday existence. These gadgets provide a practical and reachable platform for interventions using digital therapeutics. Digital therapeutics-specific mobile applications give users quick access to self-management tools, remote monitoring, learning materials, and tailored interventions.

People can interact with digital therapies anytime and anywhere due to the convenience and portability of smartphones, which gives them the ability to take charge of their health and well-being. Additionally, smartphones provide real-time feedback, reminders, and push notifications, which improve patient engagement and treatment plan adherence. Digital therapeutic solutions can collect useful health data, including activity levels, sleep patterns, and physiological measurements, by utilizing smartphone sensors and capabilities. Healthcare providers can use this data to track progress, personalize interventions, and gain insights.

Increase in Prevalence of Chronic Diseases Augmenting Digital Therapeutics Market Progress

Chronic diseases, such as diabetes, cardiovascular diseases, respiratory disorders, and mental health conditions, are on the rise globally. These conditions pose significant challenges to healthcare systems as they require long-term management and can lead to complications and reduced quality of life.

Digital therapeutics provide a promising solution by offering convenient, accessible, and personalized interventions for chronic disease management. Through mobile applications, wearable devices, and online platforms, digital therapeutics enable individuals to monitor their health, receive real-time feedback, access educational resources, and adhere to treatment plans.

Rise in prevalence of chronic diseases has created a need for innovative approaches that can improve patient outcomes, enhance self-management, and reduce healthcare costs associated with hospitalizations and emergency visits. Digital therapeutics address these needs by empowering patients to actively participate in their care, promoting behavior change, and providing continuous support between healthcare visits.

High Demand for Digital Therapeutics for Disease Treatment/Care

According to the latest digital therapeutics market trends, the treatment/care application segment held significant share in 2022. Software-based interventions can be employed for the treatment and care of various medical conditions including substance abuse, mental health issues, diabetes, respiratory disorders, and cardiovascular diseases.

Rise in need for efficient and easily accessible treatment options led by a surge in the incidence of chronic diseases worldwide is propelling the segment. Personalized interventions provided by digital therapeutics can help patients monitor their health, manage their conditions, and follow their treatment regimens. These strategies can include anything from online coaching and cognitive behavioral therapy to symptom monitoring and medication reminders.

Technological developments, such as wearables and smartphone applications, have made it possible to provide patients with treatment and care right at their fingertips. Through the provision of individualized recommendations, educational materials, and real-time feedback, these digital tools enable people to take an active role in their own care.

Digital Therapeutics Gaining Traction in B2B

According to the latest digital therapeutics market analysis, the B2B end-user segment accounted for largest share in 2022. B2B refers to the commercial relationships between digital therapeutics companies and other businesses such as healthcare providers, pharmaceutical companies, employers, and insurance companies.

Rise in awareness regarding the potential of digital therapeutics in elevating patient care is driving the segment. Healthcare providers are collaborating with digital therapeutics companies to seamlessly integrate digital solutions into current healthcare systems in order to improve patient management.

Pharmaceutical companies are collaborating with digital therapeutics startups to enhance their pharmacological therapies. Digital therapeutics can enhance medication adherence, give patients more support, and collect empirical data on the efficacy of treatments. This partnership between digital therapeutics companies and pharmaceutical companies creates new opportunities for patient care that are both comprehensive and individualized.

Regional Outlook

According to the latest digital therapeutics market forecast, North America is expected to hold largest share from 2023 to 2031. Rise in investment in R&D activities is fueling the market dynamics of the region. North America, particularly the U.S., is known for its advancements in technology and digital innovation. The region has a robust infrastructure, a high level of digital literacy, and a favorable ecosystem for the development and adoption of digital therapeutics solutions.

Surge in funding for digital therapeutics is propelling the market statistics in North America. Government programs, private equity funds, and venture capital firms are contributing to the creation and regionalization of digital therapeutics solutions. The U.S. is encouraging collaborations between digital therapeutics companies, healthcare providers, and research institutions. Thus, rise in collaborations among digital therapeutics startups, pharmaceutical giants, and technology companies is driving the digital therapeutics revenue in North America

Patients, payers, and healthcare providers in North America are increasingly adopting digital therapeutics. The region is highly digitally literate and has a culture that embraces technology to improve healthcare. A well-defined regulatory framework for digital therapeutics has been established in the U.S. The Food and Drug Administration (FDA) has established procedures and guidelines for assessing and approving digital therapeutics. Digital therapeutics companies can enter the market more easily and with greater confidence due to this regulatory clarity.

Analysis of Key Players

The global industry is consolidated, with the presence of a small number of leading players. Most players are adopting product portfolio expansion M&A strategies to increase their digital therapeutics market share.

Noom, Inc., Teladoc Health, Inc., Omada Health Inc., WellDoc Inc., Pear Therapeutics Inc., CogniFit, Ginger, Propeller Health, 2Morrow Inc., Canary Health, Click Therapeutics Inc., Akili, Cognoa, and Wellthy Therapeutics Pvt. Ltd. are prominent players operating in this market.

Each of these players has been profiled in the digital therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

  • In June 2022, Pfizer Inc. partnered with Sidekick Health to introduce a novel digital therapeutics option for Atopic Dermatitis (AD) patients. The new platform is intended to control AD patients' adherence to their prescribed regimens.
  • In February 2022, Teladoc Health, Inc. launched 'Chronic Care Complete' a novel solution for complete chronic condition management

Global Digital Therapeutics Market Snapshot

Attribute Detail
Market Value in 2022 US$ 4.5 Bn
Market Forecast Value in 2031 US$ 43.2 Bn
Growth Rate (CAGR) 28.6%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Application
    • Treatment/Care
      • Diabetes
      • Cardiovascular Diseases
      • Central Nervous System Diseases
      • Respiratory Diseases
      • Musculoskeletal Diseases
      • Medication Adherence
      • Others
    • Preventive
      • Prediabetes
      • Obesity
      • Smoking Cessation
      • Others
  • End-user
    • B2B
      • Providers
      • Payers
      • Employers
      • Pharmaceutical Companies
      • Others
    • B2C
      • Patients
      • Caregivers
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries
Companies Profiled
  • Noom, Inc.
  • Teladoc Health, Inc.
  • Omada Health Inc.
  • WellDoc Inc.
  • Pear Therapeutics Inc.
  • CogniFit
  • Ginger
  • Propeller Health
  • 2Morrow Inc.
  • Canary Health
  • Click Therapeutics Inc.
  • Akili
  • Cognoa
  • Wellthy Therapeutics Pvt. Ltd.
  • Other Prominent Players
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global digital therapeutics market in 2022?

It was valued at US$ 4.5 Bn in 2022

How big will the global digital therapeutics industry be in 2031?

It is projected to reach US$ 43.2 Bn by the end of 2031

What will be the CAGR of the digital therapeutics business during the forecast period?

It is estimated to be 28.6% from 2023 to 2031

Which are the prominent trends boosting demand for digital therapeutics?

Rise in usage of smartphones and increase in prevalence of chronic diseases

Which region is likely to record the highest demand for digital therapeutics during the forecast period?

North America is projected to record the highest demand during the forecast period

Who are the prominent digital therapeutics vendors?

Noom, Inc., Teladoc Health, Inc., Omada Health Inc., WellDoc Inc., Pear Therapeutics Inc., CogniFit, Ginger, Propeller Health, 2Morrow Inc., Canary Health, Click Therapeutics Inc., Akili, Cognoa, and Wellthy Therapeutics Pvt. Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Digital Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Application Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Digital Therapeutics Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Disease Prevalence & Incidence Rate Globally with Key Countries

        5.2. Key Industry Events

        5.3. Technological Advancement

        5.4. Insights on Digital therapeutics (DTx) for Disease Management

        5.5. COVID-19 Pandemic Impact on Industry (Value Chain And Short/Mid/Long Term Impact)

    6. Global Digital Therapeutics Market Analysis and Forecast, by Application

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Application, 2017–2031

            6.3.1. Treatment/Care

                6.3.1.1. Diabetes

                6.3.1.2. Cardiovascular Diseases

                6.3.1.3. Central Nervous System Diseases

                6.3.1.4. Respiratory Diseases

                6.3.1.5. Musculoskeletal Diseases

                6.3.1.6. Medication Adherence

                6.3.1.7. Others

            6.3.2. Preventive

                6.3.2.1. Prediabetes

                6.3.2.2. Obesity

                6.3.2.3. Smoking Cessation

                6.3.2.4. Others

        6.4. Market Attractiveness Analysis, by Application

    7. Global Digital Therapeutics Market Analysis and Forecast, by End-user

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by End-user, 2017–2031

            7.3.1. B2B

                7.3.1.1. Providers

                7.3.1.2. Payers

                7.3.1.3. Employers

                7.3.1.4. Pharmaceutical Companies

                7.3.1.5. Others

            7.3.2. B2C

                7.3.2.1. Patients

                7.3.2.2. Caregivers

        7.4. Market Attractiveness Analysis, by End-user

    8. Global Digital Therapeutics Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Digital Therapeutics Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Application, 2017–2031

            9.2.1. Treatment/Care

                9.2.1.1. Diabetes

                9.2.1.2. Cardiovascular Diseases

                9.2.1.3. Central Nervous System Diseases

                9.2.1.4. Respiratory Diseases

                9.2.1.5. Musculoskeletal Diseases

                9.2.1.6. Medication Adherence

                9.2.1.7. Others

            9.2.2. Preventive

                9.2.2.1. Prediabetes

                9.2.2.2. Obesity

                9.2.2.3. Smoking Cessation

                9.2.2.4. Others

        9.3. Market Value Forecast, by End-user, 2017–2031

            9.3.1. B2B

                9.3.1.1. Providers

                9.3.1.2. Payers

                9.3.1.3. Employers

                9.3.1.4. Pharmaceutical Companies

                9.3.1.5. Others

            9.3.2. B2C

                9.3.2.1. Patients

                9.3.2.2. Caregivers

            9.3.3. Commercial

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Application

            9.5.2. By End-user

            9.5.3. By Country

    10. Europe Digital Therapeutics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Application, 2017–2031

            10.2.1. Treatment/Care

                10.2.1.1. Diabetes

                10.2.1.2. Cardiovascular Diseases

                10.2.1.3. Central Nervous System Diseases

                10.2.1.4. Respiratory Diseases

                10.2.1.5. Musculoskeletal Diseases

                10.2.1.6. Medication Adherence

                10.2.1.7. Others

            10.2.2. Preventive

                10.2.2.1. Prediabetes

                10.2.2.2. Obesity

                10.2.2.3. Smoking Cessation

                10.2.2.4. Others

        10.3. Market Value Forecast, by End-user, 2017–2031

            10.3.1. B2B

                10.3.1.1. Providers

                10.3.1.2. Payers

                10.3.1.3. Employers

                10.3.1.4. Pharmaceutical Companies

                10.3.1.5. Others

            10.3.2. B2C

                10.3.2.1. Patients

                10.3.2.2. Caregivers

            10.3.3. Commercial

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Application

            10.5.2. By End-user

            10.5.3. By Country/Sub-region

    11. Asia Pacific Digital Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Application, 2017–2031

            11.2.1. Treatment/Care

                11.2.1.1. Diabetes

                11.2.1.2. Cardiovascular Diseases

                11.2.1.3. Central Nervous System Diseases

                11.2.1.4. Respiratory Diseases

                11.2.1.5. Musculoskeletal Diseases

                11.2.1.6. Medication Adherence

                11.2.1.7. Others

            11.2.2. Preventive

                11.2.2.1. Prediabetes

                11.2.2.2. Obesity

                11.2.2.3. Smoking Cessation

                11.2.2.4. Others

        11.3. Market Value Forecast, by End-user, 2017–2031

            11.3.1. B2B

                11.3.1.1. Providers

                11.3.1.2. Payers

                11.3.1.3. Employers

                11.3.1.4. Pharmaceutical Companies

                11.3.1.5. Others

            11.3.2. B2C

                11.3.2.1. Patients

                11.3.2.2. Caregivers

            11.3.3. Commercial

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Application

            11.5.2. By End-user

            11.5.3. By Country/Sub-region

    12. Latin America Digital Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Application, 2017–2031

            12.2.1. Treatment/Care

                12.2.1.1. Diabetes

                12.2.1.2. Cardiovascular Diseases

                12.2.1.3. Central Nervous System Diseases

                12.2.1.4. Respiratory Diseases

                12.2.1.5. Musculoskeletal Diseases

                12.2.1.6. Medication Adherence

                12.2.1.7. Others

            12.2.2. Preventive

                12.2.2.1. Prediabetes

                12.2.2.2. Obesity

                12.2.2.3. Smoking Cessation

                12.2.2.4. Others

        12.3. Market Value Forecast, by End-user, 2017–2031

            12.3.1. B2B

                12.3.1.1. Providers

                12.3.1.2. Payers

                12.3.1.3. Employers

                12.3.1.4. Pharmaceutical Companies

                12.3.1.5. Others

            12.3.2. B2C

                12.3.2.1. Patients

                12.3.2.2. Caregivers

            12.3.3. Commercial

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Application

            12.5.2. By End-user

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Digital Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Application, 2017–2031

            13.2.1. Treatment/Care

                13.2.1.1. Diabetes

                13.2.1.2. Cardiovascular Diseases

                13.2.1.3. Central Nervous System Diseases

                13.2.1.4. Respiratory Diseases

                13.2.1.5. Musculoskeletal Diseases

                13.2.1.6. Medication Adherence

                13.2.1.7. Others

            13.2.2. Preventive

                13.2.2.1. Prediabetes

                13.2.2.2. Obesity

                13.2.2.3. Smoking Cessation

                13.2.2.4. Others

        13.3. Market Value Forecast, by End-user, 2017–2031

            13.3.1. B2B

                13.3.1.1. Providers

                13.3.1.2. Payers

                13.3.1.3. Employers

                13.3.1.4. Pharmaceutical Companies

                13.3.1.5. Others

            13.3.2. B2C

                13.3.2.1. Patients

                13.3.2.2. Caregivers

            13.3.3. Commercial

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Application

            13.5.2. By End-user

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Noom, Inc.

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Teladoc Health, Inc.

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. Omada Health Inc.

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. WellDoc Inc.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Pear Therapeutics Inc.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. CogniFit

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. Ginger

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Propeller Health

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. 2Morrow Inc.

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

            14.3.10. Canary Health

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. SWOT Analysis

                14.3.10.5. Strategic Overview

            14.3.11. Click Therapeutics Inc.

                14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.11.2. Product Portfolio

                14.3.11.3. Financial Overview

                14.3.11.4. SWOT Analysis

                14.3.11.5. Strategic Overview

            14.3.12. Akili

                14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.12.2. Product Portfolio

                14.3.12.3. Financial Overview

                14.3.12.4. SWOT Analysis

                14.3.12.5. Strategic Overview

            14.3.13. Cognoa

                14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.13.2. Product Portfolio

                14.3.13.3. Financial Overview

                14.3.13.4. SWOT Analysis

                14.3.13.5. Strategic Overview

            14.3.14. Wellthy Therapeutics Pvt. Ltd.

                14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.14.2. Product Portfolio

                14.3.14.3. Financial Overview

                14.3.14.4. SWOT Analysis

                14.3.14.5. Strategic Overview

            14.3.15. Other Prominent Players

    List of Tables

    Table 01: Global Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 02: Global Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 03: Global Digital Therapeutics Market Value (US$ Bn) Forecast, by Region, 2017–2031

    Table 04: North America Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 05: North America Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 06: North America Digital Therapeutics Market Value (US$ Bn) Forecast, by Country, 2017–2031

    Table 07: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 08: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 09: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 11: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 12: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 14: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 15: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 17: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, by End-user, 2017–2031

    Table 18: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 02: Global Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 03: Global Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 04: Global Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 05: Global Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 06: Global Digital Therapeutics Market Value Share Analysis, by Region, 2022 and 2031

    Figure 07: Global Digital Therapeutics Market Attractiveness Analysis, by Region, 2023–2031

    Figure 08: North America Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 09: North America Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 10: North America Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 11: North America Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 12: North America Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 13: North America Digital Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 14: North America Digital Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

    Figure 15: Europe Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 16: Europe Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 17: Europe Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 18: Europe Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 19: Europe Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 20: Europe Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 21: Europe Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 22: Asia Pacific Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 23: Asia Pacific Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 24: Asia Pacific Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 25: Asia Pacific Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 26: Asia Pacific Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 27: Asia Pacific Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 28: Asia Pacific Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Latin America Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 30: Latin America Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 31: Latin America Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 32: Latin America Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 33: Latin America Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 34: Latin America Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 35: Latin America Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 36: Middle East & Africa Digital Therapeutics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 37: Middle East & Africa Digital Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 38: Middle East & Africa Digital Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 39: Middle East & Africa Digital Therapeutics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 40: Middle East & Africa Digital Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 41: Middle East & Africa Digital Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Middle East & Africa Digital Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 43: Global Digital Therapeutics Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved